MENLO PARK, Calif.--(BUSINESS WIRE)--May 10, 2006--Depomed, Inc. (NASDAQ:DEPO - News) today announced that it has finalized the Phase III clinical trial protocol for Gabapentin GR(TM) in conformance with requirements from the United States Food and Drug Administration (FDA). Gabapentin GR extended release tablets are in development for the treatment of postherpetic neuralgia (PHN), a long lasting pain condition caused by nerve damage during a shingles, or herpes zoster, viral infection. The company expects to begin enrollment later this month.
